Oncopeptides Announces Two Poster Presentations at the International Myeloma Workshop
The posters presented at IMW
The first poster presentation was held during Poster Session I, Multiple Myeloma Genomics – under the title: Aminopeptidase gene expression in myeloma.
The second poster presentation was held during Poster Session II, Treatment of Previously Treated Myeloma –under the title: Quality of life treatment for relapsed/refractory multiple myeloma, a systematic review.
The posters are available on the company webpage under:
www.oncopeptides.com / Investors&Media / Presentations / IMW 2019
For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Telephone: +46 8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92
This information was submitted for publication at 13.00 CET September 14, 2019.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OP-103 OCEAN) continuing enrollment. Oncopeptides’ headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
For more information please visit www.oncopeptides.com.